Who Paid My Doc
Suzanne Ludlum
Clinical Nurse Specialist, Oncology New Hyde Park, NY Nurse Practitioner
NPI 1609034719 CMS profile 11024855
450 Lakeville Rd, Monter Cancer Ctr Monter Cancer Center Monter Cancer Center, New Hyde Park, NY 11042
General payments
$244
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Suzanne Ludlum of New Hyde Park, NY is reported in the CMS Open Payments database as having received $244 across 3 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 29th percentile of Clinical Nurse Specialist, Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $107 | 1 | |
| 2023 | General | $138 | 2 |
Beside peers
- Suzanne Ludlum
- Clinical Nurse Specialist, Oncology median
- Middle half of Clinical Nurse Specialist, Oncology
- National median
In program year 2025, general payments to Suzanne Ludlum were reported at $107. Among 100 Clinical Nurse Specialist, Oncology profiles paid that year, the median was $250 and the middle half received between $100 and $1,290.
Show as a table
| Year | Suzanne Ludlum | Clinical Nurse Specialist, Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | — | — | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $0 | $260 | $105–$604 | $132 |
| 2022 | $0 | $157 | $99–$880 | $149 |
| 2023 | $138 | $244 | $95–$808 | $160 |
| 2024 | $0 | $319 | $137–$1,282 | $164 |
| 2025 | $107 | $250 | $100–$1,290 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 42 drugsPart D claims
1,314
Drug cost
$8,706,853
Branded share of claims
50.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Imbruvica Ibrutinib | Brand | 98 | $1,735,704 | |
| Calquence Acalabrutinib Maleate | Brand | 102 | $1,397,280 | |
| Brukinsa Zanubrutinib | Brand | 95 | $1,374,354 | |
| Ayvakit Avapritinib | Brand | 18 | $689,095 | |
| Revlimid Lenalidomide | Brand | 41 | $679,616 | |
| Sprycel Dasatinib | Brand | 44 | $671,546 | |
| Tasigna Nilotinib Hcl | Brand | 25 | $476,169 | |
| Bosulif Bosutinib | Brand | 23 | $394,914 | |
| Venclexta Venetoclax | Brand | 28 | $261,079 | |
| Jakafi Ruxolitinib Phosphate | Brand | 15 | $252,859 |
The 10 drugs with the highest cost, of 42 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Records
3 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Clinical Nurse Specialist, Oncology in New York
Catherine Handy
Clinical Nurse Specialist, Oncology · New York, NY
Megan Leary
Clinical Nurse Specialist, Oncology · New York, NY
Erica Fischer-Cartlidge
Clinical Nurse Specialist, Oncology · New York, NY
Suliat Adelekan
Clinical Nurse Specialist, Oncology · New York, NY
Sarah Mendez
Clinical Nurse Specialist, Oncology · New York, NY
Rose Cajuste-Bonheur
Clinical Nurse Specialist, Oncology · Poughkeepsie, NY
Related records
Clinical Nurse Specialist, Oncology in New York
Practitioners in the same specialty and state, ranked by reported value.
All Clinical Nurse Specialist, Oncology
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.